Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRNX Crinetics Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: CRNX
Price (delayed)
$30.52
Market cap
$2.86B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.81
Enterprise value
$2.81B
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate,
Highlights
The debt has declined by 3.2% year-on-year
CRNX's equity is up by 43% year-on-year but it is down by 5% since the previous quarter
The quick ratio has increased by 28% YoY but it has decreased by 2% QoQ
CRNX's gross profit has plunged by 61% YoY and by 27% from the previous quarter
The revenue has dropped by 61% year-on-year and by 27% since the previous quarter
Key stats
What are the main financial stats of CRNX
Market
Valuations
Earnings
Shares outstanding
93.68M
Market cap
$2.86B
Enterprise value
$2.81B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.26
Price to sales (P/S)
3,738.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,703.77
Revenue
$760,000
Gross profit
$760,000
Operating income
-$376.73M
Net income
-$328.25M
EBIT
-$328.25M
EBITDA
-$321.95M
Free cash flow
-$265.32M
Per share
Balance sheet
Liquidity
EPS
-$3.81
EPS diluted
-$3.81
Free cash flow per share
-$2.85
Book value per share
$13.48
Revenue per share
$0.01
TBVPS
$14.62
Total assets
$1.36B
Total liabilities
$107.33M
Debt
$50.82M
Equity
$1.25B
Working capital
$1.23B
Debt to equity
0.04
Current ratio
22.53
Quick ratio
22.24
Net debt/EBITDA
0.14
Margins
Efficiency
Dividend
EBITDA margin
-42,361.8%
Gross margin
100%
Net margin
-43,191.1%
Operating margin
-49,569.7%
Return on assets
-28.1%
Return on equity
-30.9%
Return on invested capital
-35.8%
Return on capital employed
-25.2%
Return on sales
-43,191.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRNX stock price
How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
-1.07%
1 week
-5.6%
1 month
-2.3%
1 year
-31.09%
YTD
-40.31%
QTD
-9%
Financial performance
How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$760,000
Gross profit
$760,000
Operating income
-$376.73M
Net income
-$328.25M
Gross margin
100%
Net margin
-43,191.1%
CRNX's gross profit has plunged by 61% YoY and by 27% from the previous quarter
The revenue has dropped by 61% year-on-year and by 27% since the previous quarter
The operating margin has plunged by 52% from the previous quarter
CRNX's operating income has plunged by 52% YoY and by 11% from the previous quarter
Price vs fundamentals
How does CRNX's price correlate with its fundamentals
Growth
What is Crinetics Pharmaceuticals's growth rate over time
Valuation
What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.26
P/S
3,738.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,703.77
The company's EPS fell by 3.3% QoQ
CRNX's equity is up by 43% year-on-year but it is down by 5% since the previous quarter
CRNX's P/B is 40% below its last 4 quarters average of 3.8 and 33% below its 5-year quarterly average of 3.4
The P/S is 134% above the 5-year quarterly average of 1613.5 and 3.7% above the last 4 quarters average of 3644.6
The revenue has dropped by 61% year-on-year and by 27% since the previous quarter
Efficiency
How efficient is Crinetics Pharmaceuticals business performance
The company's return on sales has shrunk by 50% QoQ
The return on invested capital rose by 28% year-on-year and by 10% since the previous quarter
The company's return on equity rose by 27% YoY
The ROA has increased by 24% YoY
Dividends
What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRNX.
Financial health
How did Crinetics Pharmaceuticals financials performed over time
The total assets rose by 39% year-on-year but it has declined by 5% since the previous quarter
The quick ratio has increased by 28% YoY but it has decreased by 2% QoQ
The debt is 96% smaller than the equity
CRNX's equity is up by 43% year-on-year but it is down by 5% since the previous quarter
CRNX's debt to equity is down by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.